Currently, there is no evidence about the use of Nrf2 activators for type 2 and type 3 HH, but it can be speculated that Nrf2 activation will also have similar therapeutic benefits for the two types of HH, as they are also caused by hepcidin deficiency, despite their different gene mutations. This evidence concerns the gene HAMP and hyperinsulinemic hypoglycemia, familial, 4.